A Phase 3 interventional study of Alendronate and Risedronate 35 mg in Postmenopausal Osteoporosis, sponsored by Organon and Co. Completed. Open to female participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
This study's enrollment of 1,053 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Browse Osteoporosis, Postmenopausal studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alendronate sodium, 70 mg, orally once weekly for up to 24 months
Drug: Alendronate · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D · Drug: Risendronate placebo
Risendronate, 35 mg, orally once weekly for up to 24 months
Drug: Risedronate 35 mg · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D · Drug: Alendronate placebo
Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Also known as: MK-0217, FOSAMAX®
Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Also known as: Actonel®, Atelvia®
Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Mean percent change from baseline in hip trochanter bone mineral density (BMD) at 12 months
Time frame: Baseline and 12 months
Mean percent change from baseline in hip trochanter BMD at 24 months
Time frame: Baseline and 24 months
Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 12 months
Time frame: Baseline and 12 months
Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 24 months
Time frame: Baseline and 24 months
Change from baseline in biochemical markers of bone turnover at 12 months
Time frame: Baseline and 12 months
Change from baseline in biochemical markers of bone turnover at 24 months
Time frame: Baseline and 24 months
Percent responders (>=0% and >=3% change from baseline in hip trochanter and lumbar spine BMD) at 12 months
Time frame: 12 months
Percent responders ((>=0% and >=3% change from baseline in hip trochanter and lumbar spine BMD) at 24 months
Time frame: 24 months
Number of participants who experienced one or more adverse events (AE)
Time frame: Up to 24 months
Number of participants who discontinued study medication due to an AE
Time frame: Up to 24 months
No study locations are listed for this record.
Ran from Sep 2002 to primary completion in Apr 2004, 19 months.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 19 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alendronate
Osteoporosis, Postmenopausal →